DDrare: Database of Drug Development for Rare Diseases

Campath, chemo and/or tbi allo sct (DrugBank: -)

3 diseases

ID	Disease name (Link within this page)	Number of trials
60	Aplastic anemia	1
62	Paroxysmal nocturnal hemoglobinuria	1
283	Acquired pure red cell aplasia	1

60. Aplastic anemia [ 218 clinical trials, 362 drugs, (DrugBank: 81 drugs), 39 drug target genes, 155 drug target pathways]

Searched query = "Aplastic anemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 218 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004143 (ClinicalTrials.gov)	September 1999	10/12/1999	Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes	Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes	Sickle Cell Anemia;Severe Aplastic Anemia;Paroxysmal Nocturnal Hemoglobinuria (PNH);Pure Red Cell Aplasia	Drug: Campath, Chemo and/or TBI Allo SCT	David Rizzieri, MD	NULL	Completed	18 Years	N/A	All	2	Phase 2	United States

62. Paroxysmal nocturnal hemoglobinuria [ 202 clinical trials, 120 drugs, (DrugBank: 25 drugs), 15 drug target genes, 90 drug target pathways]

Searched query = "Paroxysmal nocturnal hemoglobinuria", "PNH"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 202 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004143 (ClinicalTrials.gov)	September 1999	10/12/1999	Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes	Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes	Sickle Cell Anemia;Severe Aplastic Anemia;Paroxysmal Nocturnal Hemoglobinuria (PNH);Pure Red Cell Aplasia	Drug: Campath, Chemo and/or TBI Allo SCT	David Rizzieri, MD	NULL	Completed	18 Years	N/A	All	2	Phase 2	United States

283. Acquired pure red cell aplasia [ 17 clinical trials, 36 drugs, (DrugBank: 19 drugs), 16 drug target genes, 91 drug target pathways]

Searched query = "Acquired pure red cell aplasia", "Pure red cell aplasia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 17 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004143 (ClinicalTrials.gov)	September 1999	10/12/1999	Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes	Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes	Sickle Cell Anemia;Severe Aplastic Anemia;Paroxysmal Nocturnal Hemoglobinuria (PNH);Pure Red Cell Aplasia	Drug: Campath, Chemo and/or TBI Allo SCT	David Rizzieri, MD	NULL	Completed	18 Years	N/A	All	2	Phase 2	United States